Nitrowave 6.4
August 21, 2026
Glimstic G2
August 21, 2026
Glimstic G1
Glimepiride I.P. 1mg + Metformin Hydrochloride (S.R.) I.P. 500mg Bi-Layered smart Tablets
Glimstic G1 is a bilayered smart tablet specifically formulated for the effective management of type 2 diabetes mellitus. This innovative combination includes Glimepiride (1 mg) and Metformin (500 mg) sustained release (SR), designed to provide a comprehensive approach to controlling blood glucose levels in patients with diabetes.
Glimepiride, a member of the sulfonylurea class, works by stimulating the pancreas to release insulin, which is essential for lowering blood sugar levels. This mechanism is particularly effective in managing postprandial glucose levels, helping to prevent spikes in blood sugar after meals. Metformin, on the other hand, is a biguanide that enhances insulin sensitivity in peripheral tissues and reduces hepatic glucose production. The sustained release formulation of Metformin ensures a gradual release of the medication, which helps maintain stable blood glucose levels throughout the day while minimizing gastrointestinal side effects.
The combination of Glimepiride and Metformin in Glimstic G1 not only aids in achieving better glycemic control but also helps reduce the risk of diabetes-related complications. This dual-action approach is especially beneficial for patients who may not achieve adequate control with Metformin alone. By addressing multiple pathways involved in glucose regulation, Glimstic G1 provides a more effective solution for managing type 2 diabetes.
Common side effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort. Hypoglycemia is also a risk, especially if meals are missed or if there is increased physical activity.
Glimstic G1 is indicated for the management of type 2 diabetes mellitus, particularly in conjunction with diet and exercise.
Consult your healthcare provider before starting this medication, especially if you have a history of kidney or liver disease.
Store Glimstic G1 tablets in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children
Glimstic G1 is a bilayered smart tablet specifically formulated for the effective management of type 2 diabetes mellitus. This innovative combination includes Glimepiride (1 mg) and Metformin (500 mg) sustained release (SR), designed to provide a comprehensive approach to controlling blood glucose levels in patients with diabetes.
Glimepiride, a member of the sulfonylurea class, works by stimulating the pancreas to release insulin, which is essential for lowering blood sugar levels. This mechanism is particularly effective in managing postprandial glucose levels, helping to prevent spikes in blood sugar after meals. Metformin, on the other hand, is a biguanide that enhances insulin sensitivity in peripheral tissues and reduces hepatic glucose production. The sustained release formulation of Metformin ensures a gradual release of the medication, which helps maintain stable blood glucose levels throughout the day while minimizing gastrointestinal side effects.
The combination of Glimepiride and Metformin in Glimstic G1 not only aids in achieving better glycemic control but also helps reduce the risk of diabetes-related complications. This dual-action approach is especially beneficial for patients who may not achieve adequate control with Metformin alone. By addressing multiple pathways involved in glucose regulation, Glimstic G1 provides a more effective solution for managing type 2 diabetes.
